COMPASS Pathways plc
NASDAQ:CMPSMedical - Care Facilities
+$0.02 today
- Market cap
- $1.15B
- Beta
- 2.51
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$1.63
Volume 2.35M
Average 4.09M
CMPS Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
COMPASS Pathways plcNASDAQ: CMPS
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $42.83M fell 13.7% year over year, behind the -9.0% change in trailing-twelve-month operating expenses. Sequentially, it fell 6.8% from the prior quarter. Over 3 fiscal years it compounded at +17.5% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -13.7% toward the trailing-twelve-month pace of -9.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 179.04M USD
- Year-over-year change
- +0.5%
- 4-year CAGR
- +21.1%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 179.04M | +0.5% |
| FY2024 | 2024-12-31 | 178.21M | +30.2% |
| FY2023 | 2023-12-31 | 136.92M | +24.0% |
| FY2022 | 2022-12-31 | 110.4M | +32.7% |
| FY2021 | 2021-12-31 | 83.22M | — |
Operating Expenses vs competitors
How CMPS compares with its peers on the latest reported figures
- CMPS's LTM Mar 2026 operating expenses of $172.25M is the 7th highest of the 11 companies compared; the peer median is $231.88M.
- Its year-over-year change of -9.0% is the lowest of 10, against a peer median of +52.6%.
- Over three fiscal years its annual growth of +17.5% compares with a peer median of +30.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1B | +38.7% | +6.3% | 83.2% | |
| LTM Jun 2026 | $540.5M | +1.3% | +6.6% | 14997.1% | |
| LTM Jun 2026 | $493.34M | +28.7% | +25.4% | 51.4% | |
| LTM Sep 2026 | $329.22M | +502.1% | +75.3% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $254.15M | +68.1% | +35.9% | — |
| LTM Mar 2026 | $209.6M | +141.3% | +76.5% | — | |
| LTM Mar 2026 | $172.25M | -9.0% | +17.5% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $141.71M | +52.6% | +129.5% | 708.6% |
| LTM Mar 2026 | $66.42M | +28.9% | +25.5% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $46.78M | — | +121.2% | — |
| LTM Jun 2026 | $35.14M | +117.4% | -15.7% | — | |
| Peer median (excluding CMPS) | $231.88M | +52.6% | +30.7% | 395.9% | |
Competitors are the stored peer set for CMPS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.03M | 65.05M | 87.52M | 119.04M | 118.44M |
| Selling, General & Admin | 39.19M | 45.35M | 49.4M | 59.17M | 60.6M |
| Operating Expenses | 83.22M | 110.4M | 136.92M | 178.21M | 179.04M |
| Depreciation & Amortization | 175K | 330K | 242K | 233K | 216K |
| EBITDA | (71.37M) | (90.77M) | (115.24M) | (148.82M) | (285.6M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (83.22M) | (110.4M) | (136.92M) | (178.21M) | (179.04M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 4.62M | 8.27M | 7.18M |
| Interest Expense | 0 | 0 | 2.2M | 4.48M | 4.52M |
| Other Income / Expenses | 11.68M | 19.31M | 19.24M | 24.68M | (111.3M) |
| Income Before Tax | (71.54M) | (91.1M) | (117.68M) | (153.53M) | (290.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 199K | 408K | 780K | 1.59M | (2.47M) |
| Net Income | (71.74M) | (91.51M) | (118.46M) | (155.12M) | (287.86M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| EPS (Diluted) | (1.79) | (2.16) | (2.32) | (2.30) | (3.08) |
| Weighted Avg Shares | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
| Weighted Avg Shares (Diluted) | 40M | 42.44M | 51.03M | 67.48M | 93.5M |
COMPASS Pathways plc
NASDAQ:CMPS
Intrinsic Alpha fair value
Locked
Current Price
$8.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.